913815-82-4
Chemical Structure
SV119
- CAS No.: 913815-82-4
- Formula:C23H37N3O3
- Molecular Weight:403.56
SMILES: NCCCCCCN([C@@]1([H])C2)[C@](CCC1)([H])C[C@H]2OC(NC(C=C3C)=C(C=C3)OC)=O
Biological Activity: SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SV119 | SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kashiwagi H, et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007 Jul 15;6:48. [Content Brief]
- [2]. Zongyi Liu, et al. Sigma-2 receptor-induced cell death: a novel approach to triple-negative breast cancer treatment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5428.
- [3]. Hiroyuki Kashiwagi, et al. Targeted delivery of proapoptotic therapeutics in pancreas cancer. Cancer Res 1 May 2008; 68 (9_Supplement): 4084.
- [4]. Kashiwagi H, et al. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med. 2009 Mar 26;7:24. [Content Brief]
- [5]. Sun T, et al. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. Adv Healthc Mater. 2014 Aug;3(8):1283-91. [Content Brief]
Keywords
